Salatin Sara, Shafiee-Kandjani Ali Reza, Hamidi Samin, Amirfiroozi Akbar, Kalejahi Parinaz
Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Research Center of Psychiatry and Behavioral Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Per Med. 2025 Feb;22(1):29-44. doi: 10.1080/17410541.2024.2442897. Epub 2024 Dec 20.
Personalized treatment optimization considers individual clinical, genetic, and environmental factors influencing drug efficacy and tolerability. As evidence accumulates, these approaches may become increasingly integrated into standard psychiatric care, potentially transforming the treatment landscape for mental health disorders. While personalized treatment optimization shows promise in enhancing therapeutic outcomes and minimizing adverse effects, further research is needed to establish its clinical utility and cost-effectiveness across various psychiatric disorders. This review examines the potential utility of personalized treatment optimization in psychiatry, addressing the challenge of suboptimal effectiveness and variable patient responses to psychiatric medications. It explores how therapeutic drug monitoring, pharmacogenomics, and biomarker testing can be used to individualize and optimize pharmacotherapy for mental disorders such as depression, bipolar disorder, and schizophrenia.
个性化治疗优化考虑了影响药物疗效和耐受性的个体临床、遗传和环境因素。随着证据的积累,这些方法可能会越来越多地融入标准的精神科护理中,有可能改变精神疾病的治疗格局。虽然个性化治疗优化在提高治疗效果和最小化不良反应方面显示出前景,但需要进一步研究以确定其在各种精神疾病中的临床效用和成本效益。本综述探讨了个性化治疗优化在精神病学中的潜在效用,解决了疗效欠佳和患者对精神科药物反应各异的挑战。它探讨了如何利用治疗药物监测、药物基因组学和生物标志物检测来个性化和优化抑郁症、双相情感障碍和精神分裂症等精神疾病的药物治疗。